

CURRICULUM VITAE

3/03/06

GARY STEVEN GILKESON, M.D.

EDUCATION

University	1975	Bachelor of Science summa cum laude Baylor University Waco, Texas
Medical School	1979	M.D. Southwestern Medical School Dallas, Texas

POSTDOCTORAL TRAINING

Internship	1979-80	Internal Medicine North Carolina Memorial Hospital Chapel Hill, North Carolina
Residency	1980-82	Internal Medicine North Carolina Memorial Hospital Chapel Hill, North Carolina
Fellowship	1986-89	Rheumatology/Immunology Duke University Medical Center Durham, North Carolina

MILITARY SERVICE

US Air Force	1982-86	Major, Medical Corp Honorable Discharge 1986
--------------	---------	---

ACADEMIC APPOINTMENTS

Staff Internist	1982-86	Department of Internal Medicine Carswell AFB Regional Hospital, Texas
Clinical Associate	1983-86	Department of Internal Medicine Southwestern Medical School Dallas, Texas
Associate in Medicine	1989-90	Duke University Medical Center Durham, North Carolina

Assistant Professor of Medicine	1990-95	Duke University Medical Center
Chief, Rheumatology	1992-96	Durham VA Medical Center
Senior Staff	1994-96	Duke Comprehensive Cancer Center
Assistant Professor of Immunology	1994-96	Duke University Medical Center
Associate Professor of Medicine	1995-96	Duke University Medical Center
Associate Professor of Medicine (tenured)	1996-	Medical University of South Carolina
Chief of Rheumatology	1996-	Ralph H. Johnson VA Medical Center
Associate Professor of Microbiology/Immunology	1996-	School of Graduate Studies, MUSC
Graduate Faculty	1999	MUSC School of Marine Biosciences,
Professor of Medicine and Microbiology/Immunology	2000	Medical University of South Carolina

LICENSURE

Licensed	1983	State of North Carolina inactive
	1996	State of South Carolina

CERTIFICATIONS AND ORGANIZATIONS

Certified	1982	American Board of Internal Medicine
	1988	American Board of Internal Medicine, Subspecialty Rheumatology
Memberships	1987	American College of Rheumatology
	1987	American Association for the Advancement of Science
	1990	American Federation of Medical Research
	1994	American Association of Immunologists
	1997	Southern Society of Clinical Investigation
	1999	International Complement Society

AWARDS AND HONORS

Undergraduate

Omicron Delta Kappa
Alpha Chi

Medical School

Alpha Omega Alpha-3rd year
Texas Congressional Merit Scholar
Merck Scholar

Awards

Senior Rheumatology Scholar Award,
American College of Rheumatology, 1989

Henry Christian Award for
Excellence in Research, American
Federation of Clinical Research, 1993

Arthritis Foundation, National Volunteer
Service Award, 2000

Physician of the Year, Ralph H Johnson
VAMC, 2001

Selected to Best Doctors in America,
2002-06

Arthritis Foundation Research Hero,
2001

Kirkland Scholar in Lupus, Hospital for
Special Surgery, 2003-2006

Lupus Clinical Trials Consortium Center
Director, 2003-

Advisory Boards

Board of Trustees, Carolina's Chapter
Arthritis Foundation, 1992-
Chapter Chairman, 1993-1996

Arthritis Foundation
National Board of Delegates 1993-4
Scientific and Medical Committee 1995-7
Corporate Promotions Task Force 1999-
Professional Education Committee,
1997-00

Scientific and Medical Committee 2000
-2

Professional Ed Task Force
(Chairperson 2001)
Scientific and Medical Council 2005-

National Peer Review Council
Molecular Biology Study Section
Arthritis Foundation, 1993-1995
Chairman, 1994,1995

American College of Rheumatology
Communication and Marketing
Committee,
Head, Internet Task Force, 1996-99
CME Committee, 2000-2003
Committee on Research 2004-7
Annual Meeting Planning Committee
2005-7

NIH General Medicine A1 Study Section
standing member, 1997-2001
Immunological Studies ad hoc member
2003
Chair, MCRC Study Section, 2005

American College of Rheumatology
Lupus Study Group, 1998-2003

Lupus Foundation
Medical Advisory Board, 1999-
Chairperson, 2004-
Board of Directors 2005-

Veterans Administration Research
Service National Medical Research
Advisory Group 2001-2003

NIAMS Lupus Biomarkers Working
Group, 2003-

NIH Lupus Advisory Group 2005-

Research and Education Foundation,
American College of Rheumatology,
Chair of Grants Peer Review Council
2005

Editorial Boards

MKSAP, 1997 edition, Rheumatology
Associate Editor, Journal of Immunology
1998-2004
Clinical Immunology 2000-2004
ACR News 1997-2000
Lupus News 1999-2001
Autoimmunity, 2002-

Ad hoc Reviewer

Journal of Immunology
Clinical Immunology and Immunopathology
Arthritis and Rheumatism
Journal of Rheumatology
Proceedings of the National Acad Sci, USA
Blood
Journal of Investigative Dermatology
Kidney International
Journal of Clinical Investigation

MUSC/VA service

MUSC Faculty Senate 2001-2004
MUSC Conflict of Interest Committee
1999-2004
Cancer Center/DOD Advisory Board
VA IACUC (Chair) 1997-2003
MUSC University Research Council,
vice chair 2004-
MUSC Faculty Tenure and Promotion
Committee 2003-
MUSC School of Medicine Deans
Research Advisory Council 2005-
MUSC Space Allocation Committee
CTSA Pilot and Translational studies
working group- Chair, 2006

CURRENT RESEARCH SUPPORT

1. Estrogen receptors and lupus

Principal Investigator: Gary S. Gilkeson, M.D.

Agency: Veterans Administration Type: Merit Review Period: 10/1/95-9/30/2009

Assess the role of estrogen receptors in lupus.

2. Role of nitric oxide in systemic lupus erythematosus

Principal Investigator: Gary S. Gilkeson, M.D.

Agency: NIAMS Type: NIH RO1 AR45476 Period 4/1/99-2/28/08

Aims to study the utility of nitric oxide (NO) as a marker of lupus disease activity as well as its potential as a therapeutic target. Seeks to define the tissue effects of NO in disease, the immune mediators that lead to NO production, and if PBMC apoptosis is aberrant in human lupus and the role NO plays in apoptosis in human lupus.

3. Multidisciplinary Clinical Research Center for Rheumatic Diseases in African Americans

Principal Investigator: Richard Silver MD, Gary Gilkeson MD co-PI and PI of Project 3

Agency: NIH Type: P60 AR049459 Period 4/15/03-3/31/08

The goal of this project is to determine the environmental and genetic interactions resulting in poor renal outcome of African Americans with lupus nephritis.

7. Role of histone deacetylase inhibitors in the treatment of systemic lupus erythematosus

Principal Investigator: Nila Mishra MD, Gary Gilkeson MD co PI

Agency: Alliance for Lupus Research Period: 2/1/03-1/31/07

The goal of this research is to determine the potential for the use of histone deacetylase inhibitors for the treatment of lupus.

8. Targeted complement inhibition in lupus nephritis

Principal Investigator: Steven Tomlinson, Gary Gilkeson MD coPI

Agency: Alliance for Lupus Research Period: 1/01/04-12/30/06

The goal of this research is to use targeted complement inhibitors for treating lupus nephritis

9. Innate immune system in arthritis

Principal Investigator: V Mike Holers, Gary Gilkeson MD co PI

Agency: NIAMS Type: NIH RO1AR58942 Period 12/1/04-11/30/09

10. Lupus Clinical Trials Consortium

Center Director: Gary Gilkeson, MD

Agency: Lupus Clinical Trials Consortium Period: 4/1/04-3/31/06

11. Kirkland Scholar Award

Principal Investigator: Gary Gilkeson, MD

Agency: Kirkland Foundation Period: 9/1/03-8/31/06

12. NIH T32 training grant in inflammatory and fibrotic diseases.

PI: Gary Gilkeson, MD

Agency: NIAMS Period: 7/01/05-6/30/10

12. VA REAP award

PI: John Raymond. Co-PI Gary Gilkeson

Agency: VA Period: 10/01/2000-9/30/2010

PUBLICATIONS

- 1) Gilkeson G, Teng R, Stone M, et.al. Detection of myoglobin in human sera by RIA; its utility as an Emergency Room screening procedure for myocardial infarction. Am. Heart J. 95: 70-77, 1978.

- 2) Gilkeson G, Delaney R. Effectiveness of sublingual clonidine in patients unable to take oral medications. *Drug Intell. Clin. Pharm.* 21: 262-264, 1987
- 3) Gilkeson G, and Caldwell D. Multiple Acyl CoA Dehydrogenase deficiency presenting as a proximal myopathy. *Arthritis Rheum.* 31: 695-696, 1988.
- 4) Gilkeson G, Polisson R, Sinclair H, Vogler J, Rice J, Caldwell D, Spritzer C, Martinez S. Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of Magnetic Resonance Imaging. *J. Rheumatol.* 15: 1361-1366, 1988.
- 5) Gilkeson G, Rice J. Retroperitoneal fibrosis: the forgotten collagen vascular disease. *N.C. Med. J.* 50: 192-194, 1989.
- 6) Shergy W, Gilkeson G, German D. Acute gouty arthritis and intravenous nitroglycerin. *Arch. Intern. Med.* 148: 2505-2506, 1988.
- 7) Gilkeson G, Grudier J, Karounos D, Pisetsky D. Induction of anti-ds DNA antibodies in normal mice by immunization with bacterial DNA. *J. Immunol.* 142:1482-1486, 1989.
- 8) Blum F, Gilkeson G, Greenberg C, Murray J. Migratory superficial thrombophlebitis in association with a lupus anticoagulant. *Int.J.Derm.* 29:190-192, 1990.
- 9) Gilkeson G, Grudier J, Pisetsky D. Response of normal mice to immunization with DNA of various specie origin. *Clin. Immunol. Immunopathol.* 51:362-371, 1989.
- 10) Gilkeson G, Ruiz P, Grudier J, Kurlander R, Pisetsky D. Genetic control of inflammatory arthritis in lpr congenic mice. *Clin. Immunol. Immunopathol.* 53:460-474, 1989.
- 11) Pisetsky D, Grudier J, Gilkeson G. The role of immunogenic DNA in the pathogenesis of systemic lupus erythematosus. *Arthritis Rheum.* 33:153-159, 1990.
- 12) Wu D, Gilkeson G, Armitage J, Reich C, Pisetsky D. Selective recognition of DNA antigenic determinants by murine monoclonal antibodies. *Clin. Exp. Immunol.* 82:33-37, 1990.
- 13) Gilkeson G, Pritchard J, Pisetsky D. Cellular requirements for anti-DNA responses in normal mice. *Eur. J. Immunol.* 20:1789-1794, 1990.
- 14) Gilkeson G, Grudier J, Pisetsky D. Specificity of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. *Clin. Immunol. Immunopath.* 59:288-300, 1991.
- 15) Gilkeson G, Ruiz P, Pritchard A, Pisetsky D. Genetic control of inflammatory arthritis and glomerulonephritis in congenic lpr mice and their F1 hybrids. *J. Autoimmunity.* 4:595-606, 1991.
- 16) Gilkeson G, and Pisetsky D. Effects of structural alterations induced by procainamide on DNA antigenicity. *Life Science Advances: Immunol.* 10:63-68, 1991.
- 17) Messina J, Gilkeson G, Pisetsky D. Stimulation of in vitro lymphocyte proliferation by bacterial DNA. *J. Immunol.* 147:1759-1764, 1991.

- 18) Robertson C, Gilkeson G, Ward M, Pisetsky D. Patterns of heavy and light chain utilization in the antibody response to DNA in normal human subjects and patients with systemic lupus erythematosus. *Clin. Immunol. Immunopath.* 62:25-32, 1992.
- 19) Gilkeson G, Spurney R, Coffman T, Ruiz P, Kurlander R, Pisetsky D. Effect of anti-CD4 treatment on inflammatory arthritis in MRL-lpr/lpr mice. *Clin. Immunol. Immunopath.* 64:166-172, 1992.
- 20) Watson M, Rao J, Gilkeson G, Ruiz P, Eicher E, Pisetsky D, Matsuzawa A, Rochelle J, Seldin M. Genetic analysis of MRL-lpr mice: Relationship of the Fas apoptosis gene to disease manifestations and renal disease modifying loci. *J. Exp. Med.* 176:1645-1656, 1992.
- 21) Pyun E, Pisetsky D, Gilkeson G. The fine specificity of monoclonal anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. *J. Autoimmunity* 1, 11-26, 1993.
- 22) Messina J, Gilkeson G, Pisetsky D. DNA structural requirements for induced lymphocyte proliferation. *Cell. Immunol.* 147:148-157, 1993.
- 23) Bernstein K, Bolshoun D, Gilkeson G, Munns T, Lefkowitz J. Glomerular binding activity in sera detected in a membrane based in vitro assay. *Clin. Exp. Immunol.* 91:449-455, 1993.
- 24) Gilkeson G, Ruiz P, Howell D, Lefkowitz J, Pisetsky D. Induction of immune mediated glomerulonephritis in normal mice immunized with bacterial DNA. *Clin. Immunol. Immunopath.* 68:282-292, 1993.
- 25) Gilkeson G, Bloom D, Pisetsky D, Clarke S. Molecular characterization of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. *J. Immunol.* 151:1353-1364, 1993.
- 26) Palmer S, Gilkeson G, Pisetsky D. The effect of sex on the induction of anti-DNA antibodies in normal mice immunized with bacterial DNA. *Lupus* 2: 251-255, 1993.
- 27) Weinberg J, Pisetsky D, Seldin M, Misukonis M, Phippen A, Ruiz P, Wood E, Granger D, Gilkeson, G. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease. *J. Exp. Med.* 179:651-660, 1994.
- 28) Gilkeson G, Phippen A, Pisetsky D. Induction of crossreactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by bacterial DNA immunization. *J. Clin. Invest.* 95:1398-1402, 1995.
- 29) Gilkeson G, Bernstein K, Phippen A, Clarke S, Marion T, Pisetsky D, Ruiz P, Lefkowitz J. The effect of somatic mutations within clonal sets of anti-DNA antibodies on specificity and pathogenicity. *Clin. Immunol. Immunopath* 76:59-67, 1995.
- 30) Polisson R, Gilkeson G, Smith E, Pisetsky D, Simon L. A pilot trial of gamma interferon in the treatment of patients with scleroderma; correlation of response with serum IL-2r levels. *J. Rheumatol.* 23:654-664, 1996.
- 31) Gilkeson G, Ruiz P, Alexander A, Phippen A, Lefkowitz J, Pisetsky D. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. *J. Exp. Med.* 183:1389-1398, 1996.
- 32) Taylor G, Lee D, Carballo E, Lee D, Lai WS, Thompson M, Patel D, Schankman D, Gilkeson G, Broxmeyer HE, Haynes B, Blackshear P. A pathogenetic role

- for tumor necrosis factor α in the syndrome of cachexia, arthritis and autoimmunity resulting from tristetraprolin (TTP) deficiency. *Immunity* 4:445-453, 1996.
- 33) Wloch M, Alexander A, Phippen A, Lefkowitz J, Pisetsky D, Gilkeson G. Differences in V κ gene utilization and VH CDR3 sequence among anti-DNA from C3H-lpr mice and lupus mice with nephritis. *Eur. J. Immunol.* 26:2225-2232, 1996.
 - 34) Lefkowitz J, Di Valerio R, Norris J, Glick G, Alexander A, Jackson L, Gilkeson G. Molecular characteristics of glomerulotropic autoantibodies in murine lupus. *J. Immunol.* 157:1298-1305, 1996.
 - 35) St. Clair E, Wilkinson W, Lang T, Mishukonis M, Sanders L, Pisetsky D, Gilkeson G, Granger D, Weinberg B. Systemic activation of blood mononuclear cells for nitric oxide synthase type 2 expression in rheumatoid arthritis. *J. Exp. Med.* 184:1173-1179, 1996.
 - 36) Privalle CT, Keng T, Gilkeson GS, Weinberg JB. The role of nitric oxide and peroxynitrite in the pathogenesis of spontaneous murine autoimmune disease. In: *The biology of nitric oxide*. J. Stamler, SS Gross and S Moncada, Portland Press, London. 20, 1996. Vol 5.
 - 37) Korompilias AV, Gilkeson GS, Ortel TL, Seaber AV, Urbaniak JR. Anticardiolipin antibodies and osteonecrosis of the femoral head. *Clin. Orth.* 345:174-180, 1997.
 - 38) Wloch MK, Phippen AM, Alexander A, Lefkowitz J, Pisetsky P, Gilkeson G. Molecular characteristics of induced anti-DNA antibodies in pre-autoimmune NZB/NZW mice. *J. Immunol.* 158: 4500-4506, 1997.
 - 39) Oates, J, Alexander A, Ruiz P, Phippen A, Gilkeson, G. Effect of late modulation of nitric oxide production on murine lupus. *Clin. Immunol. Immunopath.* 83:86-92, 1997.
 - 40) Gilkeson G, Mudgett J, Seldin M, Mishukonis M, Alexander A, Weinberg. Serologic and clinical disease activity in MRL-lpr mice lacking NOS2. *J. Exp. Med.* 186:365-373, 1997.
 - 41) Carballo E, Gilkeson G, Blackshear P. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. *J Clin. Invest* 100:986-995, 1997.
 - 42) Wloch M, Clarke S, Gilkeson G. Effect of VH CDR3 and light chain use on binding of an anti-DNA antibody from a bacterial DNA immunized mouse. *J Immunol.* 159:6083- 6090, 1997.
 - 43) Weinberg JB, Gilkeson GS, Mason RP, Chamultrat W. Nitrosylation of blood hemoglobin and renal non-heme proteins in autoimmune MRL-lpr/lpr mice. *Free Radical Biology in Medicine.* 24:191-196, 1998.
 - 44) Watanabe H, Sherris D, Gilkeson G. Effect of soluble CD16 on disease in NZB/NZW mice. *Clin Immunol Immunopath.* 88:91-91, 1998.
 - 45) Gilkeson G, Cannon C, Oates J, Reilly C, Petri M. Correlation of a serum measure of nitric oxide production with clinical disease activity measures of lupus. *J Rheum.* 26:318-324, 1999.
 - 46) Gilkeson G, Conover J, Pisetsky D, Feagin A, Halpern M, Klinman D. Effect of bacterial DNA on cytokine production by (NZB/NZW) F1 mice. *J Immunol.* 161:3890-3895, 1998

- 47) Reilly C, Oates J, Morrow J, Cook J, Halushka P, Gilkeson G. Modulation of mesangial cell activation in MRL/lpr mice by prostaglandin J2. *J Immunol.*164:1498-1504,2000.
- 48) Molano I, Watanabe H, Wloch M, Alexander A, Gilkeson G. Effect of a genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production in Fas^{lpr} mice. *Clin Immunol.*94:24-32, 2000.
- 49) Mohan C, Morel L, Yang P, Watanabe H, Gilkeson G, Croker B, Wakeland E. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. *J Clin Invest.* 103:1685-1695, 1999.
- 50) Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. *Proc Assoc Amer Phys.* 111(6):611-621, 1999.
- 51) Watanabe H, Circolo A, Holers M, Boackle S, Colten H, Wetsel R, Gilkeson G. Modulation of renal disease in MRL/lpr mice deficient in complement Factor B. *J Immunol.* 164:786-794, 2000.
- 52) Korompilias V, Gilkeson G. Hemorrhage and thrombus formation in early experimental osteonecrosis. *Clinical Orthopaedics and Related Research.* 386:11-18, 2001
- 53) Morel L, Croker B, Blenman K, Huang G, Gilkeson G, Wakeland E. Genetic reconstitution of SLE immunopathology with poly-congenic B6.NZM strains. *Proc Natl Acad Sci. USA* 97:6670-6675, 2000.
- 54) Guyton K, Bond R, Reilly C, Gilkeson G, Halushka P, Cook J. Differential effects of 15-deoxy-Delta(12,14)-prostaglandin J(2) and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation.] *J Leuk Bio.* 69:631-638, 2001.
- 55) Reilly CM, Oates JC, Sodian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. *Clin Immunol.* 98:337-345, 2001
- 56) Privalle CT, Keng T, Gilkeson GS, Weinberg JB. Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. *Molec Med.* 6:779-792, 2000.
- 57) Pandey J, Cooper G, Treadwell E, Gilkeson G, St. Clair E, Dooley MA. Immunoglobulin GM and KM allotypes in systemic lupus erythematosus. *Exp Clin Immunogenetics.* 18:117-122, 2001.
- 58) Sekine H, Reilly C, Molano I, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SM, Gilkeson GS. Complement Component C3 is Not Required for Full Expression of Immune Complex Glomerulonephritis in MRL/lpr Mice. *J Immunol.* 166:6444-6451, 2001.
- 59) Oates J, Reilly C, Crosby M, Gilkeson G. PPAR agonists; potential use anti-inflammatory agents. *Arthritis Rheum* 46:598-605, 2002
- 60) Reilly C, Farrelly L, Viti D, Redmond S, Hutchison F, Ruiz P, Manning P, Connor J, Gilkeson G. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. *Kidney Int.* 61:839-846, 2002.

- 61) Parks CG, Cooper GS, Nylander-French LA, Sanderson WT, Dement JM, Cohen PL, Dooley MA, Treadwell EL, St Clair E, Gilkeson GS, Hoppin JA, Savitz DA. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: A population-based, case-control study in the Southeastern United States. *Arthritis Rheum.* 46:1840-50, 2002.
- 62) Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: Results of a population-based, case-control study. *Arthritis Rheum.* 46(7):1830-9, 2002.
- 63) Cooper GS, Treadwell EL, St Clair EW, Dooley MA, Gilkeson GS. Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. *J Rheum.* 28:2653-2656, 2001.
- 64) Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. *J Clin Epidemiol.* 55:982-9, 2002.
- 65) Cooper GS, Parks CG, Treadwell EL, EW St. Clair, Gilkeson GS, Cohen PL, Roubey RAS, Dooley MA. Differences by Race, Sex, and Age in the Clinical and Immunologic Features of Recently-Diagnosed Systemic Lupus Erythematosus Patients in the Southeastern United States. *Lupus.* 11:161-7,2002.
- 66) Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. *J Clin Invest.* 111:539-552, 2003.
- 67) Fraser PA, Ding WZ, Mohseni M, Treadwell EL, Dooley MA, St Clair EW, Gilkeson GS, Cooper GS. Glutathione s-transferase m null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: a possible gene-environment interaction for autoimmunity. *J Rheumatol.* 30:276-82, 2003.
- 68) Peden-Adam MM, Eudaly J, Eudaly E, Dudley A, Zeigler J, Lee A, Robbs J, Gilkeson G, Keil DE. Evaluation of immunotoxicity induced by single or concurrent exposure to N,N-diethyl-m-toluamide (DEET), pyridostigmine bromide (PYR), and JP-8 jet fuel. *Toxicol Ind Health.* 17:192-209, 2003.
- 69) Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. *J Immunol.* 170:1517-23, 2003.
- 70) Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, Gilkeson GS. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans. *J Rheumatol.* 30:60-7, 2003.
- 71) Guyton K, Zingarelli B, Ashton S, Teti G, Tempel G, Reilly C, Gilkeson G, Halushka P, Cook J. Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. *Shock.* 20:56-62, 2003.
- 72) Molano ID, Redmond S, Sekine H, Zhang XK, Reilly C, Hutchison F, Ruiz P, Gilkeson GS. Effect of genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production and renal disease in MRL/lpr mice. *Clin Immunol.* 107:186-97, 2003.

- 73) Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. *Kidney Int.* 65:129-138,2004.
- 74) Parks CG, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. *Ann Rheum Dis.* 63:91-94,2004.
- 75) Croker BP, Gilkeson G, Morel L. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. *Genes Immun.* 4:575-85,2003.
- 76) Cooper GS, Treadwell EL, Dooley MA, Clair EW, Gilkeson GS, Taylor JA. N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus. *J Rheumatol.* 31:76-80,2004.
- 77) Sekine H, Watanabe H, Gilkeson GS. Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Faslpr mice. *J Immunol.* 172:3913-21,2004.
- 78) Oates JC, Gilkeson GS. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. *J Investig Med.* 52:62-71,2004.
- 79) M.M. Peden-Adams, A.C Dudley, J.G. EuDaly, C.T. Allan, G.S. Gilkeson, D.E. Keil. (2004) Pyridostigmine Bromide (PYR) Alters Immune Function in B6C3F1 Mice. *Immunopharmacology and Immunotoxicology-* 26:1-15, 2004.
- 80) D. E. Keil, A. C. Dudley, J. G. EuDaly, J. Dempsey, G. S. Gilkeson, M. M. Peden-Adams A Profile of Immunological and Hematological Effects Observed in B6C3F1 Mice Exposed To JP-8 Jet Fuel for 14 Days. *Journal of Toxicology and Environmental Health-* 67:1109-29, 2004
- 81) Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Dooley MA. Occupational risk factors for the development of systemic lupus erythematosus. *J Rheumatol.* 31:1928-33,2004.
- 82) Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, Gilkeson GS. PPAR $\{\gamma\}$ is not necessary for synthetic PPAR $\{\gamma\}$ agonist inhibition of iNOS and Nitric Oxide. *J Pharmacol Exp Ther.* 2004 Sep 8 [Epub ahead of print]
- 83) Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA, Gilkeson GS. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. *J Immunol.* 173:4171-8,2004.
- 84) Douglas G, Reilly C, Dooley MA, Page G, Cooper G, Gilkeson G. Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus. *J Rheumatol.* 31:1756-62,2004.
- 85) Parks CG, Pandey JP, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Feghali-Botswick CL, Cooper GS. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. *Hum Immunol.* 65:622-31,2004.

- 86) Zhang J, Gallant S, Molano I, Watson D, Spyropoulos D, Ruiz P, Gilkeson G. Decreased expression of the Ets family Fli-1 transcription factor markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. *J Immunol* 173:6481-9, 2004.
- 87) Parks CG, Hudson LL, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States. *Lupus*. 13:784-91, 2004
- 88) Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. *Mol Immunol*. 2005 42:87-97, 2005.
- 89) Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med*. 353(21):2219-28, 2005.
- 90) Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ, Gilkeson GS. Inflammatory modulation of PPAR γ expression and activity. *Clin Immunol*. 2005 Nov 19; [Epub ahead of print]
- 91) Bouali H, Gilkeson G. New therapies and preventive strategies to treat and minimize damage in lupus. *Curr Rheumatol Rep*. 2005 Dec;7(6):457-62.
- 92) Crosby MB, Svenson J, Gilkeson GS, Nowling TK. A novel PPAR response element in the murine iNOS promoter. *Mol Immunol*. 42(11):1303-10. 2005.
- 93) Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. *Arthritis Rheum*. 2005 52:1148-59, 2005.
- 94) Haraldsson MK, dela Paz NG, Kuan JG, Gilkeson GS, Theofilopoulos AN, Kono DH. Autoimmune alterations induced by the New Zealand Black Lbw2 locus in BWF1 mice. *J Immunol*. 2005 174:5065-73, 2005.
- 95) Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev*. 2006;5:114-7, 2006.
- 96) Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, Behrens TW. Genomic view of systemic autoimmunity in MRL/lpr mice. *Genes Immun*. 2006;7(2):156-68.
- 97) Peden-Adams MM, Eudaly JG, Heesemann LM, Smythe J, Miller J, Gilkeson GS, Keil DE. Developmental Immunotoxicity of Trichloroethylene (TCE): Studies in B6C3F1 Mice. *J Environ Sci Health A Tox Hazard Subst Environ Eng*. 2006;41(3):249-71.
- 98) Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med*. 2005;353(21):2219-28.
- 99) Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ, Gilkeson GS.

- Inflammatory modulation of PPARgamma expression and activity.
Clin Immunol. 2006;118(2-3):276-83.
- 100) Bouali H, Gilkeson G. New therapies and preventive strategies to treat and minimize damage in lupus
.Curr Rheumatol Rep. 2005;7(6):457-62.

REVIEWS/CHAPTERS

- 1) Gilkeson G, Caldwell D. Rheumatologic associations with malignancy. J. Musculoskeletal Med. 7:64-82, 1990.
- 2) Gilkeson G, Allen N. Retroperitoneal fibrosis, a true connective tissue disease. Rheum. Dis. Clin. N.A. 22:23-37, 1996.
- 3) Lefkowitz J, Gilkeson G. Nephritogenic autoantibodies in lupus: Current concepts and continuing controversies. Arthritis Rheum. 39:894-903, 1996.
- 4) Pisetsky D, Gilkeson G, St. Clair EW. Systemic lupus erythematosus; Diagnosis and treatment. Med. Clin. NA. 81:113-127, 1997.
- 5) Gilkeson G. Inflammatory Mediators. Primer on the Rheumatic Diseases. 11th Edition. 1997.
- 6) Gilkeson G, Anderson P. Scientific Basis of Rheumatic Diseases. American College of Physicians Medical Knowledge Self Assessment Program (MKSAP), Rheumatology. 2nd edition, 1997.
- 7) Gilkeson G. Glomerulotrophic autoantibodies in lupus. in Pathogenesis of Systemic Lupus Erythematosus. Kammer G, Tsokos G. Eds. Humana Press, pg 448-470, 1999.
- 8) Cooper G, Dooley MA, Treadwell E, St. Clair EW, Gilkeson G. Environmental and hormonal influences on the development of systemic lupus erythematosus. Arthritis Rheum. 41:1714-1724, 1998.
- 9) Gilkeson G. Humoral response. in Molecular Rheumatology. Tsokos G. Eds. Humana Press 2000 pp59-74.
- 10) Gilkeson G. Nitric oxide and related compounds. In Arthritis and Associated Conditions; A Textbook in Rheumatology. Ed Koopman W. Lippincott, Williams and Wilkins 2001, pp236-248
- 11) Oates J, Gilkeson G. Inflammatory Mediators. Primer on the Rheumatic Diseases. 12th Edition. 2001 pp 81-88
- 12) Reilly C and Gilkeson G. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunologic Research 25:143-153, 2002.
- 13) Oates J, Gilkeson G. Inflammatory mediators in lupus nephritis. Current Reviews in Rheumatology 2002;14(5):498-503.
- 14) Oates J, Gilkeson G. Nitric oxide and related compounds. In Arthritis and Associated Conditions; A Textbook in Rheumatology. 15th edition Ed Koopman W. Lippincott, Williams and Wilkins 2004, pp 541-556.

- 15) Brown A, Gilkeson G. Fibrosing Syndromes. In Arthritis and Associated Conditions; A Textbook in Rheumatology. 15th edition Ed Koopman W. Lippincott, Williams and Wilkins 2004, pp.2093-2108.